Merck & Co. Inc. (MRK)

The performance of healthcare companies is relatively uncorrelated with broader macroeconomic growth.

One great thing about a crash or downturn in the markets is that it can allow you to go bargain hunting fairly easily. Many stocks have been falling this year, and if you're a dividend investor, you k...

When the market is reaching toward all-time highs, I tend to start building a cash pile. When the market starts to get quite volatile and brings declines, that can create opportunities for putting som...

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on New $1 billion Biologics Center of Excellence in Wilmington, Delaware.

U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall St...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

April's market volatility has created dividend bargains, allowing investors to pick high-quality blue-chip stocks with strong balance sheets and long-term return potential. Merck, trading at a low P/E...

The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.